Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) FCF Margin (2020 - 2025)

Ovid Therapeutics' FCF Margin history spans 6 years, with the latest figure at 1444.85% for Q4 2025.

  • For Q4 2025, FCF Margin changed N/A year-over-year to 1444.85%; the TTM value through Dec 2025 reached 528.13%, up 1090983.0%, while the annual FY2025 figure was 528.13%, 937399.0% up from the prior year.
  • FCF Margin reached 1444.85% in Q4 2025 per OVID's latest filing, up from 9751.52% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 77.21% in Q1 2021 to a low of 121865.19% in Q3 2022.
  • Average FCF Margin over 5 years is 13429.26%, with a median of 8207.69% recorded in 2025.
  • The largest YoY upside for FCF Margin was 11263766bps in 2023 against a maximum downside of -1613580bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 5.5% in 2021, then increased by 24bps to 4.18% in 2022, then decreased by -29bps to 5.38% in 2023, then crashed by -160493bps to 8635.84% in 2024, then skyrocketed by 83bps to 1444.85% in 2025.
  • Per Business Quant, the three most recent readings for OVID's FCF Margin are 1444.85% (Q4 2025), 9751.52% (Q3 2025), and 75.8% (Q2 2025).